To investigate the safety of switch from infliximab biosimilar 1 in rheumatoid arthritis patients.

To investigate the safety of switch from infliximab biosimilar 1 in rheumatoid arthritis patients. - Switch from infliximab to infliximab biosimilar 1 in rheumatoid arthritis patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021492

Enrollment

Registered

2016-03-20

Start date

2016-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

switch from infliximab to infliximab biosimilar 1 in rheumatoid arthritis patients.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: rheumatoid arthritis treated infliximab

Exclusion criteria

Exclusion criteria: 1.Patients who corresponds to a contraindication of infliximab of infliximab biosimilar 1 2.Patients their doctors find not appropriate for this study

Design outcomes

Primary

Measure	Time frame
Change in safety and efficacy before and after switch prescripution.	—

Countries

Japan

Contacts

Public ContactMakoto Inoue

Inoue Hospital Dpepartment of Rheumatology

m2inoue@marianna-u.ac.jp027-322-3660

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026